Levi & Korsinsky announces the commencement of a class action lawsuit in the USDC for the Southern District of New York on behalf of shareholders of Aratana Therapeutics, Inc. (NASDAQ: PETX) who purchased shares between March 16, 2015 and February 3, 2017.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.